Home › Funds › Bain Capital Life Sciences Investors, LLC › CCCC

Bain Capital Life Sciences Investors, LLC position in CCCC

C4 THERAPEUTICS INC · Health Care

Bain Capital Life Sciences Investors, LLC reported holding 7,171,910 shares of CCCC (C4 THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$23.9M, representing 1.64% of its reported portfolio and ranking #14 among its reported holdings. Bain Capital Life Sciences Investors, LLC has disclosed CCCC holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)7.17M sh
Reported value held$23.88M
Portfolio Weight1.64%
First reportedQ3 2023
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Bain Capital Life Sciences Investors, LLC's CCCC position evolved

Bain Capital Life Sciences Investors, LLC first disclosed a stake in CCCC in Q3 2023 at 1,642,210 shares (US$3.1M). The position peaked in Q2 2026 at 7,171,910 shares, worth US$33.5M. Across 13 filings, Bain Capital Life Sciences Investors, LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 7,171,910 shares valued at US$23.9M. Notable position changes include a 30% trim in Q1 2024 (shares fell 43% over the following quarter), a 545% increase in Q4 2025 (shares rose 38% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.64M $3.05M New
Q4 2023 1.64M $9.28M Hold
Q1 2024 1.14M $9.33M Reduce
Q2 2024 1.11M $5.14M Reduce
Q3 2024 1.11M $6.34M Hold
Q4 2024 1.11M $4.00M Hold
Q1 2025 1.11M $1.78M Hold
Q2 2025 1.11M $1.59M Hold
Q3 2025 1.11M $2.47M Hold
Q4 2025 7.17M $13.70M Add
Q1 2026 7.17M $18.86M Hold
Q2 2026 7.17M $33.49M Hold
Q3 2026 7.17M $23.88M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CCCC and 13F data

CCCC (C4 THERAPEUTICS INC) is a Health Care company. 46 other funds we track also report a position in CCCC — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$37.4M), Lynx1 Capital Management LP (US$34.2M), Soleus Capital Management, L.P. (US$15.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CCCC

All CCCC fund holders →

FAQ

How long has Bain Capital Life Sciences Investors, LLC held CCCC?

Bain Capital Life Sciences Investors, LLC has disclosed CCCC holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Bain Capital Life Sciences Investors, LLC's current position in CCCC?

As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 7.17M shares of CCCC (C4 THERAPEUTICS INC), valued at $23.88M, representing 1.64% of its reported portfolio and ranking #14.

Has Bain Capital Life Sciences Investors, LLC been buying or selling CCCC?

In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC held unchanged its position in CCCC. The position peaked in Q2 2026 at 7.17M shares.

Which other funds hold CCCC?

Other major institutional holders of CCCC include RA CAPITAL MANAGEMENT, L.P., Lynx1 Capital Management LP, Soleus Capital Management, L.P., among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.